Related Experiment Video
Updated: Jul 21, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting
Chuanying Geng1, Wenming Chen2, Hong-Hu Zhu3,4
1Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Abstract:
CAR-T therapy is rapidly reshaping the treatment paradigm of multiple myeloma (MM). At the 2025 ASH Annual Meeting, pivotal trials demonstrated marked efficacy across both relapsed/refractory and newly diagnosed settings. In KarMMa-3, a subgroup analysis of older patients (≥ 70 years) showed idecabtagene vicleucel significantly improved outcomes versus standard care: overall response rate (ORR) 81.6% vs. 48.1%, median progression-free survival (PFS) 18.9 vs. 5.7 months, with median overall survival (OS) not reached in either arm. CARTITUDE-4 showed superior 30-month PFS (71.0% vs. 43.2%), while iMMagine-1 reported an ORR of 97% with 93% minimal residual disease negativity. Notably, frontline CAR-T studies achieved unprecedented outcomes, including 100% ORR, stringent complete response rates approaching 94-97%, and 30-month PFS and OS rates of 88-92%. Together, these data support a paradigm shift toward earlier integration of CAR-T therapy in MM management.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy

